Company: NMP
Filing Date: 2025-05-06
Form Type: S-1
Source: 0001213900-25-039851
Chunk: 204

Company: NMP Acquisition Corp.
Filing Date: 2025-05-06
Form: S-1
Chunk 204
---
 of Medicine and a M.A.C.M. from the University of Southern California Keck School of Medicine. Dr. Singh is well qualified to serve on our board of directors because of her significant experience in pharmaceuticals, health care and policy, as well as her private and public company experience as a member of the board of directors of such companies. Number, Terms of Office and Election of Officers and Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will consist of five members. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint officers as it deems appropriate pursuant to our amended and restated memorandum and articles of association. Prior to the closing of our initial business combination, only holders of our founder shares will be entitled to vote on the appointment and removal of our directors prior to consummation of our initial business combination and holders of our public shares will not have the right to vote on the appointment and removal of directors during such time. These provisions of our amended and restated memorandum and articles of association may only be amended by a special resolution passed by an affirmative vote of at least 90% of such shareholders who are eligible to vote and attend and vote in a general meeting our shareholders. Director Independence Nasdaq’s listing standards require that a majority of our board of directors be independent. An “independent director” is defined generally as a person who has no material relationship with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have three “independent directors” as 130 defined in the Nasdaq listing standards and applicable SEC rules prior to completion of this offering. Our board has determined that Ms. Priya, Mr. Benson and Dr. Singh are independent directors under applicable SEC and Nasdaq rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Officer and Director Compensation None of our officers or directors have received any cash compensation for services rendered to us, except that our sponsor may transfer founder shares, to our three independent director nominees for their board service, for nominal cash consideration prior to the closing of this offering. Other than as set forth elsewhere in this prospectus, there will be no fees, reimbursements or cash payments made by the company to our